Exploring the Role of Adipocyte Fatty Acid Binding Protein in the Association of Obstructive Sleep Apnea and Metabolic Dysfunction

Not Applicable

Completed

• Conditions: Obstructive Sleep Apnea; Metabolic Syndrome; Insulin Resistance; Inflammation
• Interventions: Device: continuous positive airway pressure

• Registration Number: NCT01173432
• Lead Sponsor: The University of Hong Kong

Brief Summary

Adipocyte fatty acid binding protein (A-FABP) is a member of the FABP super family, is abundant in adipocytes and macrophages. Regulatory functions of A-FABP in lipid and glucose metabolism have been described, and it is suggested to play an important role in the pathogenesis of metabolic syndrome.We hypothesize that obstructive sleep apnea (OSA) may upregulate A-FABP production and thus causally contribute to metabolic dysfunction. Our group has recently demonstrated that A-FABP, expressed and secreted from adipocytes, is present in the blood stream .The levels of A-FABP correlated with various metabolic variates in the metabolic syndrome. Furthermore, we have obtained novel data in men with a range of sleep disordered breathing showed that the duration of oxygen desaturation correlated with circulating levels of A-FABP, independent of age and waist/body mass index. The current proposal aims to pursue this finding and further explore the role of A-FABP in the association of OSA and metabolic dysfunction.

Detailed Description

We hypothesize that there are changes in circulating A-FABP level which can be mitigated by effective treatment of OSA.

The aim is to investigate the effect of CPAP treatment of OSA on circulating A-FABP, and other metabolic biomarkers and cardiovascular parameters

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2010-07-29
• Study First Submitted QC: 2010-07-30
• Study First Posted: 2010-08-02
• Primary Completion: 2018-12
• Study Completion: 2018-12
• Status Verified: 2019-04
• Last Update Submitted: 2019-04-16
• Last Update Posted: 2019-04-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Subjects between 18 - 65 years old
• Able to understand and give informed written consent

Exclusion Criteria

• BMI > 35 kg/m2, and features of obesity hypoventilation syndrome
• known diabetes mellitus or hyperlipidemia on treatment
• known cardiovascular disease except hypertension stable on treatment
• unstable medical illness
• need for starting treatment for OSA or other medical conditions immediately

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
continuous positive airway pressure	continuous positive airway pressure	using continuous positive airway pressure (CPAP) device during sleep, for the study period (4 weeks)

Primary Outcome Measures

Name	Time	Method
adipocyte fatty acid binding protein	changes over 4 weeks of CPAP treatment	blood assay

Secondary Outcome Measures

Name	Time	Method
Lipids and lipoprotein	changes over 4 weeks of CPAP treatment	blood assay
Insulin and glucose	changes over 4 weeks of CPAP treatment	blood assay
blood Markers of oxidative stress and fat metabolism	changes over 4 weeks of CPAP treatment
blood inflammatory markers	changes over 4 weeks of CPAP treatment
Epworth sleepiness scale	changes over 4 weeks of CPAP treatment	by sleep questionnaire
blood pressure	changes over 4 weeks of CPAP treatment

Trial Locations

Locations (1)

The University of Hong Kong; 🇭🇰 Hong Kong, Hong Kong